PRESS RELEASES

Date Title and Summary View
Toggle Summary GlycoMimetics Receives Japanese Patent For Uproleselan (GMI-1271)
Issued patent expands global patent portfolio for GlycoMimetics’ late-stage drug candidate targeting treatment of broad spectrum of patients with acute myeloid leukemia (AML) ROCKVILLE, Md. --(BUSINESS WIRE)--Aug. 14, 2018-- GlycoMimetics, Inc. (NASDAQ: GLYC), a biopharmaceutical company focused on
View HTML
Toggle Summary GlycoMimetics Reports Second Quarter 2018 Results and Highlights Recent Company Achievements
Announced a Cooperative Research and Development Agreement (CRADA) to collaborate with the National Cancer Institute (NCI) and the Alliance for Clinical Trials in Oncology to fund a planned pivotal Phase 3 trial to evaluate uproleselan (GMI-1271) in older, newly diagnosed acute myeloid leukemia
View HTML
Toggle Summary GlycoMimetics to Report Second Quarter 2018 Financial Results on August 9, 2018
ROCKVILLE, Md. --(BUSINESS WIRE)--Aug. 2, 2018-- GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will report its second quarter 2018 financial results on Thursday August 9, 2018 , and will host a conference call and webcast on Friday, August 10, 2018 , at 8:30 a.m. ET .
View HTML
Toggle Summary GlycoMimetics to Present at Jefferies 2018 Global Healthcare Conference
ROCKVILLE, Md. --(BUSINESS WIRE)--Jun. 1, 2018-- GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that Chief Executive Officer Rachel King will provide a company overview at the Jefferies Annual Health Care Conference in New York , on Thursday, June 7, 2018 , at 11:30 a.m. ET .
View HTML
Toggle Summary GlycoMimetics Announces NCI-Sponsored Pivotal Trial of GMI-1271 in Older, Newly Diagnosed AML Patients Fit for Intensive Chemotherapy
Third of three planned trials positions GlycoMimetics to address unmet needs across the AML spectrum ROCKVILLE, Md. --(BUSINESS WIRE)--May 30, 2018-- GlycoMimetics, Inc. (NASDAQ: GLYC), a biopharmaceutical company focused on discovering and developing novel small-molecule drug candidates to treat
View HTML
Toggle Summary GlycoMimetics Reports First Quarter 2018 Results
Based on guidance from the US Food and Drug Administration ( FDA ), announced study design for GlycoMimetics -sponsored Phase 3 trial of candidate GMI-1271 in relapsed/refractory AML Signed study startup agreement with European consortium to prepare to conduct a trial in a second AML indication,
View HTML
Toggle Summary GlycoMimetics to Report First Quarter 2018 Financial Results on May 3, 2018
ROCKVILLE, Md. --(BUSINESS WIRE)--Apr. 26, 2018-- GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will host a conference call and webcast to report its first quarter 2018 financial results on Thursday, May 3, 2018 , at 8:30 a.m. ET . The dial-in number for the conference call is (844)
View HTML
Toggle Summary GlycoMimetics Announces Pricing of Public Offering of Common Stock
ROCKVILLE, Md. --(BUSINESS WIRE)--Mar. 20, 2018-- GlycoMimetics, Inc. (Nasdaq:GLYC), a clinical-stage biotechnology company focused on the discovery and development of novel glycomimetic drugs, today announced the pricing of its underwritten public offering of 7,000,000 shares of its common stock
View HTML
Toggle Summary GlycoMimetics Announces Proposed Public Offering of Common Stock
ROCKVILLE, Md. --(BUSINESS WIRE)--Mar. 19, 2018-- GlycoMimetics, Inc. (Nasdaq: GLYC), a clinical-stage biotechnology company focused on the discovery and development of novel glycomimetic drugs, today announced that it intends to offer and sell, subject to market conditions, 4,500,000 shares of its
View HTML
Toggle Summary GlycoMimetics to Present New Preclinical Data for GMI-1271 and GMI-1359 at AACR Annual Meeting 2018
Data supports expanding use of GMI-1271 in patients with AML who are unfit for chemotherapy GMI-1359 shows potential in treating osteosarcoma and other cancers ROCKVILLE, Md. --(BUSINESS WIRE)--Mar. 14, 2018-- GlycoMimetics, Inc. (NASDAQ: GLYC) announced today that preclinical research suggesting
View HTML